Saturday, August 21, 2021 7:33:47 PM
Regen BioPharma Inc (OTCMKTS: RGBP) Mega Runner as Biotech Moves Towards “Pink Current” & Cancer Vaccine Patent Approved
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-mega-runner-as-biotech-moves-towards-pink-current-cancer-vaccine-patent-approved/132685/
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful run up the charts after the Company’s Cancer Vaccine Patent was approved August 17th 2021 Exclusively for RGBP which will be announced once the Company uplists to “pink current” According to the USPTO: Antigen specific mRNA cellular cancer vaccines are cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
Big things are expected to happen here once RGBP goes pink current with the stock already under heavy accumulation as RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE!
(OTCMKTS: RGBP) is a publicly traded biotechnology company focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a very valuable patent porfolio.
RGBP is led by CEO David Koos who has over 30 years of investment banking and venture capital experience. He has a deep knowledge of startup businesses, public markers and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance. Additionally, he has authored / co–authored numerous peer reviewed journal articles. Dr. Koos has been working hard behind the scenes getting all the filings into OTC Markets Group in order to go “pink current”
Big things happening here:
1). on 4/8/21 he files an 8K which in and of itself is a dead give-a-away of what he’s up to. The question begs why would he file an 8K that specifically gives himself exclusive control of voting rights in negotiations for the sale of the company during the bidding process that’s specifically intended to prevent a Hostile Take Over? And in doing this he states quote: “persons of interest who want to ACQUIRE RGBP must negotiate directly.” This is in reference to himself having sole control of voting rights that this 8K gives him. Other words, negotiations for sale of the company can’t go around him to his board which is a typical move in any hostile take over. This by itself reveals what he’s up to in addition to MANY other factors shown below. https://sec.report/Document/0001607062-21-000145/
2). he recently hired a Firm to get OTC current with FULL disclosure reporting. This has to do not only with SEC compliance to remain listed on the OTC beyond September 2021 but ALSO it provides transparency for any potential Big Pharma buyers that would never consider buying a company otherwise.
3). on 6/1/21 he files another 8K that has to do with resolving a lawsuit. This would be important to any potential buyers for reason a pending unresolved lawsuit would likely complicate negotiations of a buy out, or it would be a deterrent altogether. https://sec.report/Document/0001607062-21-000145/
4). we see him moving to get all his expired Patents updated. Logically this move would be consistent with preparing for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline.
5). lastly he’s not updating the company website that’s been outdated for years. Why would he invested time, energy, and money in updating his company website if he’s about to sell the company?
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) (RGBP subsidiary) entered into an agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall: pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021, pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter. pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment. ONCP is trading at $33 at an $847 million market valuation, the 50,000 shares are worth $1,500,000)
https://twitter.com/jtb36/status/1428493043791892480
RGBP Chart
On July 13 RGBP filed an 8k listing the Company’s issued patents and pending patents:
GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS): Patent No: 8263571
METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION: PatentNo :11,053,503
METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND: Patent No: 10,088,485
MODULATION OF NR2F6 AND METHODS AND USES THEREOF: Patent No: 9091696
IP for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the USPTO intends to issue a patent: ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES: Application Number: 15/162,370
IP for which Patent Protection has expired due to non payment of fees for which revival is in process: METHOD OF CANCER TREATMENT USING SIRNA SILENCING Patent No: 8389708
IP for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress. UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS: Application Number: 15/494,358
Active Patent Applications: ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL; Application Number 17035955.
REDUCTION OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION. Application Number 17037284
SUPPRESSION OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6 Application Number 17087386
STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY Application Number 17010720
SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS Application Number 15820324
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY. Application Number 15364111
Patent issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL.
CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES: Patent Number: 10,030,227
Antigen specific mRNA cellular cancer vaccines provides a means of generating cellular therapies for cancer through the administration of mRNA that is chemically modified to allow for in vitro entry into cells. Particularly the invention teaches that mRNA encoding the survivin peptides a) STFKNWPFL (SEQ ID NO: 1); b) STFKNWPFMRYMILGLLAL (SEQ ID NO: 2); c) TTALSSTFKNWPFL (SEQ ID NO: 3); d) MASTFKNWPFAAAAAG (SEQ ID NO: 4) may be administered to dendritic cells, said dendritic cells being useful as a stimulator of anticancer immunity.
The invention provides means of inducing an anti-cancer response in a mammal, comprising the steps of initially “priming” the mammal by administering an agent that causes local accumulation of antigen presenting cells. Subsequently, a tumor antigen is administered in the local area where said agents causing accumulation of antigen presenting cells is administered. A time period is allowed to pass to allow for said antigen presenting cells to traffic to the lymph nodes. Subsequently a maturation signal, or a plurality of maturation signals are administered to enhance the ability of said antigen presenting cell to activate adaptive immunity. In some embodiments of the invention activators of adaptive immunity are concurrently given, as well as inhibitors of the tumor derived inhibitors are administered to derepress the immune system.
RGBP is making a powerful run up the charts after the Company’s Cancer Vaccine Patent was approved August 17th 2021 Exclusively for RGBP which will be announced once the Company uplists to “pink current” According to the USPTO: Antigen specific mRNA cellular cancer vaccines are cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity. Big things are expected to happen here once RGBP goes pink current with the stock already under heavy accumulation as RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.
Sign Up now for our 100% FREE Penny Stock Newsletter
Your E-mail...
Submit
Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article
TAGSrgbp
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-mega-runner-as-biotech-moves-towards-pink-current-cancer-vaccine-patent-approved/132685/
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful run up the charts after the Company’s Cancer Vaccine Patent was approved August 17th 2021 Exclusively for RGBP which will be announced once the Company uplists to “pink current” According to the USPTO: Antigen specific mRNA cellular cancer vaccines are cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
Big things are expected to happen here once RGBP goes pink current with the stock already under heavy accumulation as RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE!
(OTCMKTS: RGBP) is a publicly traded biotechnology company focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a very valuable patent porfolio.
RGBP is led by CEO David Koos who has over 30 years of investment banking and venture capital experience. He has a deep knowledge of startup businesses, public markers and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance. Additionally, he has authored / co–authored numerous peer reviewed journal articles. Dr. Koos has been working hard behind the scenes getting all the filings into OTC Markets Group in order to go “pink current”
Big things happening here:
1). on 4/8/21 he files an 8K which in and of itself is a dead give-a-away of what he’s up to. The question begs why would he file an 8K that specifically gives himself exclusive control of voting rights in negotiations for the sale of the company during the bidding process that’s specifically intended to prevent a Hostile Take Over? And in doing this he states quote: “persons of interest who want to ACQUIRE RGBP must negotiate directly.” This is in reference to himself having sole control of voting rights that this 8K gives him. Other words, negotiations for sale of the company can’t go around him to his board which is a typical move in any hostile take over. This by itself reveals what he’s up to in addition to MANY other factors shown below. https://sec.report/Document/0001607062-21-000145/
2). he recently hired a Firm to get OTC current with FULL disclosure reporting. This has to do not only with SEC compliance to remain listed on the OTC beyond September 2021 but ALSO it provides transparency for any potential Big Pharma buyers that would never consider buying a company otherwise.
3). on 6/1/21 he files another 8K that has to do with resolving a lawsuit. This would be important to any potential buyers for reason a pending unresolved lawsuit would likely complicate negotiations of a buy out, or it would be a deterrent altogether. https://sec.report/Document/0001607062-21-000145/
4). we see him moving to get all his expired Patents updated. Logically this move would be consistent with preparing for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline.
5). lastly he’s not updating the company website that’s been outdated for years. Why would he invested time, energy, and money in updating his company website if he’s about to sell the company?
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) (RGBP subsidiary) entered into an agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall: pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021, pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter. pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment. ONCP is trading at $33 at an $847 million market valuation, the 50,000 shares are worth $1,500,000)
https://twitter.com/jtb36/status/1428493043791892480
RGBP Chart
On July 13 RGBP filed an 8k listing the Company’s issued patents and pending patents:
GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS): Patent No: 8263571
METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION: PatentNo :11,053,503
METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND: Patent No: 10,088,485
MODULATION OF NR2F6 AND METHODS AND USES THEREOF: Patent No: 9091696
IP for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the USPTO intends to issue a patent: ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES: Application Number: 15/162,370
IP for which Patent Protection has expired due to non payment of fees for which revival is in process: METHOD OF CANCER TREATMENT USING SIRNA SILENCING Patent No: 8389708
IP for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress. UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS: Application Number: 15/494,358
Active Patent Applications: ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL; Application Number 17035955.
REDUCTION OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION. Application Number 17037284
SUPPRESSION OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6 Application Number 17087386
STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY Application Number 17010720
SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS Application Number 15820324
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY. Application Number 15364111
Patent issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL.
CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES: Patent Number: 10,030,227
Antigen specific mRNA cellular cancer vaccines provides a means of generating cellular therapies for cancer through the administration of mRNA that is chemically modified to allow for in vitro entry into cells. Particularly the invention teaches that mRNA encoding the survivin peptides a) STFKNWPFL (SEQ ID NO: 1); b) STFKNWPFMRYMILGLLAL (SEQ ID NO: 2); c) TTALSSTFKNWPFL (SEQ ID NO: 3); d) MASTFKNWPFAAAAAG (SEQ ID NO: 4) may be administered to dendritic cells, said dendritic cells being useful as a stimulator of anticancer immunity.
The invention provides means of inducing an anti-cancer response in a mammal, comprising the steps of initially “priming” the mammal by administering an agent that causes local accumulation of antigen presenting cells. Subsequently, a tumor antigen is administered in the local area where said agents causing accumulation of antigen presenting cells is administered. A time period is allowed to pass to allow for said antigen presenting cells to traffic to the lymph nodes. Subsequently a maturation signal, or a plurality of maturation signals are administered to enhance the ability of said antigen presenting cell to activate adaptive immunity. In some embodiments of the invention activators of adaptive immunity are concurrently given, as well as inhibitors of the tumor derived inhibitors are administered to derepress the immune system.
RGBP is making a powerful run up the charts after the Company’s Cancer Vaccine Patent was approved August 17th 2021 Exclusively for RGBP which will be announced once the Company uplists to “pink current” According to the USPTO: Antigen specific mRNA cellular cancer vaccines are cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity. Big things are expected to happen here once RGBP goes pink current with the stock already under heavy accumulation as RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition and the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Koos is presently on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.
Sign Up now for our 100% FREE Penny Stock Newsletter
Your E-mail...
Submit
Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article
TAGSrgbp
C4urself the 1st Ammendment.
Don't assume that i don't know, and i wont assume, that you have no idea.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
